Jardiance or Farxiga With Ozempic or Mounjaro: Taking an SGLT2 and a GLP-1

Yes. An SGLT2 inhibitor such as Jardiance or Farxiga and a GLP‑1 such as Ozempic or Mounjaro are taken together every day, no label forbids it, and the diabetes guidelines name the two classes side by side. On blood sugar and weight the effects add up, and that is measured in randomized trials. On heart attacks and kidney failure the case for the pair is good but indirect: subgroups and cohorts, not a trial built to test it. The place the two drugs actually collide is fluid and ketones. A GLP‑1 makes people eat less and sometimes vomit. The SGLT2 labels list both as triggers for dehydration and for ketoacidosis.

What the labels say about each other

Nothing restrictive. The three SGLT2 labels limit use in type 1 diabetes and warn about insulin and sulfonylureas; none bars a GLP‑1.^[2][3][4] Farxiga’s label goes further and describes a trial of the pair: 694 adults on metformin given dapagliflozin with exenatide, a weekly GLP‑1.^[3] On the other side, Mounjaro’s label lists SGLT2 inhibitors among the background drugs in its diabetes trials, with 32% of patients on one in SURPASS‑3 and 25% in SURPASS‑4.^[6] Ozempic’s label reports that 16% of the people in its kidney trial, FLOW, were on an SGLT2 inhibitor.^[5]

The guidelines treat the classes the same way. The 2026 ADA Standards recommend a GLP‑1 “and/or” an SGLT2 inhibitor for adults with type 2 diabetes and heart disease or high cardiovascular risk, regardless of A1C (grade A).^[1] Contrast that with the one pairing the same section advises against: a GLP‑1 with a DPP‑4 inhibitor, because it adds no further glucose lowering.^[1] SGLT2 drugs work in the kidney rather than on the incretin system, so there is no such overlap.

Blood sugar and weight: the trials that added one to the other

Four randomized trials put the two classes together and reported the result. Three were in type 2 diabetes; one was in adults with obesity and no diabetes.^{[8][11][12][13]}

DURATION‑8 is the cleanest test of whether the weight effects add, because it had all three arms. They nearly do. Exenatide alone took off 1.56 kg and dapagliflozin alone 2.22 kg; together, 3.55 kg, a little under the sum of the two.^[9] The pair also beat either drug on A1C and blood pressure,^[8] and the gains held in an exploratory two-year follow-up, though only 62% of patients completed it.^[10] The trial was funded by AstraZeneca.^[8]

SUSTAIN 9 is the trial closest to the question most readers have: semaglutide added to people who were already on an SGLT2 inhibitor. It lowered A1C by 1.42 points and weight by 3.81 kg more than placebo over 30 weeks.^[11] AWARD‑10 did the same with dulaglutide and found the same direction on A1C.^[12]

Two limits matter for anyone taking these drugs for weight. First, every trial above used older GLP‑1s or diabetes doses. We found no randomized trial of an SGLT2 inhibitor added to semaglutide 2.4 mg (Wegovy) or to tirzepatide at weight-loss doses. Second, the SGLT2 contribution is modest, a couple of kilograms, and none of the three SGLT2 labels lists weight loss as an indication.^[2][3][4] People usually end up on both because each drug is there for a different reason: the SGLT2 for the heart or kidneys, the GLP‑1 for sugar or weight.

Heart and kidneys: additive on paper, untested head to head

No randomized trial has compared the combination with either drug alone on heart attacks, strokes, heart failure or kidney failure. The ADA’s kidney chapter says so plainly: there have been no studies directly comparing these drug classes.^[21] What exists is a stack of indirect evidence, and it mostly points the same way.

• GLP‑1 outcome trials, split by SGLT2 use. A 2024 meta-analysis pooled three trials with 17,072 people, 10.2% of them on an SGLT2 inhibitor. The hazard ratio for major cardiac events on a GLP‑1 was 0.77 in people taking an SGLT2 and 0.79 in those not, with no sign of a difference between the groups, though the smaller group’s estimate was less precise. Kidney and heart-failure effects did not differ by SGLT2 use either.^[14]
• SGLT2 outcome trials, split by GLP‑1 use. The mirror analysis pooled 12 SGLT2 trials with 73,238 people with diabetes, only 4.2% on a GLP‑1. The SGLT2 benefits on heart and kidney outcomes were consistent with or without one.^[15]
• Oral semaglutide. In SOUL, 2,596 of 9,650 participants were on an SGLT2 inhibitor at baseline. The hazard ratio for major cardiac events was 0.89 in that group and 0.84 in the rest, a difference the trial could not distinguish from chance.^[17]

The awkward result is FLOW, the semaglutide kidney trial. Among the 550 people already on an SGLT2 inhibitor, the main kidney-and-heart outcome happened to 41 of 277 on semaglutide and 38 of 273 on placebo, a hazard ratio of 1.07. Among those not on one it was 0.73.^[16] Ozempic’s label prints the finding:

The treatment benefit on the primary composite endpoint was not evident in patients taking SGLT2 inhibitors at baseline, but there were few events in these patients.

— Ozempic (semaglutide) prescribing information, section 14

The trial’s authors read it differently. The test for a real difference between the two groups was not significant (P = 0.109), the effects on cardiac events and death were similar in both, and the subgroup was small; they concluded the kidney benefit was consistent, while conceding the power to detect a smaller effect was limited.^[16] Both readings can be true. FLOW neither proves the GLP‑1 adds kidney protection on top of an SGLT2 nor shows that it does not. A larger kidney synthesis, which found the benefit held regardless of SGLT2 use, is covered in where the evidence is strongest.

The rest of the evidence for the combination comes from people who chose it, which makes it weaker than it looks.

In the UK cohort, adding an SGLT2 to a GLP‑1 was linked to 30% fewer major cardiac events and 57% fewer serious kidney events; adding a GLP‑1 to an SGLT2 was linked to 29% fewer cardiac events, with a kidney estimate too wide to read.^[18] The 2026 review of 18 cohorts found larger associations still, and graded nearly all of them low or very low certainty, adding that “residual confounding cannot be overcome”.^[19] The newest piece, an exploratory network meta-analysis published in August 2026, found the combination ranked first on every outcome, with fewer cardiac events and heart-failure admissions than an SGLT2 alone and a slower kidney decline than a GLP‑1 alone. Its authors call the results hypothesis-generating, because the combination arm rests largely on non-randomized subgroups inside other trials.^[20]

The ADA reads the same pile without overreaching. It notes that the mechanisms differ and that the evidence for combining is growing, then leaves it to the clinician’s judgment, weighing the person’s other conditions and preferences, which drug to start first and “whether combination therapy is warranted”.^[21]

Where the two drugs meet: fluid

An SGLT2 inhibitor works by making the kidneys spill sugar into the urine, and water follows it. The Jardiance label warns that this can cause volume depletion, showing up as low blood pressure on standing or a sudden rise in creatinine, and reports acute kidney injury after approval, some cases needing dialysis. It names who is most at risk: people with reduced kidney function (eGFR under 60), older adults, and anyone on a loop diuretic such as furosemide.^[2] Invokana’s label says the same in five words: volume depletion “may result in acute kidney injury”.^[4]

Every GLP‑1 label carries the matching warning from the other direction. Most reported kidney injuries on Ozempic and Mounjaro happened in people dehydrated by nausea, vomiting or diarrhea, and the labels tell patients to take precautions against fluid loss.^[5][6][7] Put the two together and the risk is easy to trace: one drug pulls water out through the urine, the other can cut intake and add losses through the gut. On an ordinary day neither matters much. On a day of vomiting, both push the same way. What those warnings mean for the kidneys over the longer run is covered in GLP-1 drugs and your kidneys.

Ketoacidosis with near-normal blood sugar

This is the rarer and more serious overlap. All three SGLT2 labels warn of ketoacidosis, including fatal cases in type 2 diabetes reported after approval. The Jardiance label lists what tends to set it off, and two of the triggers are things a GLP‑1 does by design or by side effect:^[2]

Precipitating conditions for diabetic ketoacidosis or other ketoacidosis include under-insulinization due to insulin dose reduction or missed insulin doses, acute febrile illness, reduced caloric intake, ketogenic diet, surgery, volume depletion, and alcohol abuse.

— Jardiance (empagliflozin) prescribing information, section 5.1

Two details make it easy to miss. Blood sugar may be lower than expected, under 250 mg/dL, so a normal-looking glucose reading does not rule it out. And the symptoms the label lists, nausea, vomiting, abdominal pain, malaise and shortness of breath, are close to the ordinary side effects of starting or raising a GLP‑1.^[2] Someone on both drugs who is vomiting and feels unusually unwell has two explanations, and only one of them is harmless.

The trial data hint at the mechanism without showing harm. Farxiga’s label reports that in the exenatide combination trial, 1.7% of people on both drugs had a serum bicarbonate of 13 mEq/L or lower, a marker of acid build-up, against 0.4% on either drug alone.^[3] A published case describes a 36-year-old man with new type 2 diabetes who developed severe ketoacidosis within days of starting semaglutide and dapagliflozin together, after persistent vomiting and very little carbohydrate intake; he needed intensive care and recovered fully.^[23]

What that does not give you is a rate. The large cohort review found no difference in ketoacidosis between combination and single-drug users, though events were too few to pool,^[19] and an analysis of FDA adverse-event reports found ketoacidosis reported proportionally less often with the pair than with an SGLT2 alone.^[22] Spontaneous reports cannot measure risk, so neither result settles it.

Genital infections and low blood sugar

Genital yeast infections are the SGLT2’s own side effect, because sugar in the urine feeds them. On the Jardiance label they affected 5.4% to 6.4% of women against 1.5% on placebo, and 1.6% to 3.1% of men against 0.4%; Farxiga’s figures are similar.^[2][3] We found no evidence that adding a GLP‑1 changes that, and the cohort review saw no difference in genitourinary infections.^[19]

Low blood sugar is not a feature of this pairing on its own. Both sets of labels name the same culprits, insulin and insulin secretagogues such as sulfonylureas, and suggest lowering those doses when either drug is added.^[2][6] In DURATION‑8 no one on the combination had a major or minor low.^[8] In SUSTAIN 9, four people on semaglutide (2.7%) had a severe or confirmed low, in a trial where 12.9% were also taking a sulfonylurea.^[11] The 2026 ADA Standards ask prescribers adding any new drug to reassess sulfonylureas, meglitinides and insulin for exactly this reason.^[1] Who is actually at risk of a low on a GLP‑1 is worked through in GLP-1 drugs and low blood sugar.

Two drugs in practice

Stomach side effects come mostly from the GLP‑1. In SUSTAIN 9, they affected 37.3% of people adding semaglutide against 13.2% on placebo,^[11] and they follow the GLP‑1’s usual pattern of peaking after each dose increase. The SGLT2 adds more urination and thirst, which the Jardiance label reports in a few percent of users.^[2]

The bigger obstacle is often not biology. Each drug is covered and billed on its own, often with its own prior authorization, and approval for one says nothing about the other. A pragmatic trial that tried to test the pair in ordinary care found that many people prescribed both never filled both, and half of those who started stopped at least one; that study is covered in why combination therapy fails in practice. If metformin is the third drug in the mix, metformin and a GLP-1 together covers its own dehydration link.

What to ask a prescriber

1. What is each drug for? If the SGLT2 is there for heart failure or kidney disease, it is doing a job the GLP‑1 does not replace, even if weight or sugar improves.
2. Do my other medicines need to change? Ask specifically about insulin, sulfonylureas and diuretics.
3. What should I do on a sick day? Ask which drug to pause, if any, when you are vomiting, not eating or running a fever, and when to restart.
4. Should I check ketones? The SGLT2 labels suggest considering ketone monitoring in people at risk, as the situation calls for.^[2]
5. What about procedures? Tell whoever schedules surgery or an endoscopy that you take both, since each has its own instructions beforehand.